Implantable devices for pain control: spinal cord stimulation and intrathecal therapies

Krames, Elliot

doi:10.1053/bean.2002.0263

Cited by 68 publications

(40 citation statements)

References 92 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Additionally, it has been reported that i.t. administration with morphine provides analgesia in patients with neuropathic pain syndromes (Krames 2002). Considering these reports, we propose here that the discrepancy and the effectiveness of morphine may be partly related to the timing of the treatment relative to the duration of the neuropathy.…”

Section: Inhibition Of Morphine-or Oxycodone-induced Place Preferencementioning

confidence: 81%

Comparative Pharmacological Profiles of Morphine and Oxycodone under a Neuropathic Pain-Like State in Mice: Evidence for Less Sensitivity to Morphine

Narita

Nakamura

Masahiko

et al. 2007

Neuropsychopharmacol

View full text Add to dashboard Cite

The present study was undertaken to investigate pharmacological actions induced by morphine and oxycodone under a neuropathic pain-like state. In the m-opioid receptor (MOR) binding study and G-protein activation, we confirmed that both morphine and oxycodone showed MOR agonistic activities. Mice with sciatic nerve ligation exhibited the marked neuropathic pain-like behavior. Under these conditions, antinociception induced by subcutaneously (s.c.) injected morphine was significantly decreased by sciatic nerve ligation, whereas s.c. injection of oxycodone produced a profound antinociception in sciatic nerve-ligated mice. There were no significant differences in spinal or supraspinal antinociception of morphine and oxycodone between sham operation and nerve ligation. Moreover, either morphine-or oxycodone-induced increase in guanosine-5 0 -o-(3-thio) triphosphate ([ 35 S]GTPgS) binding in the spinal cord, periaqueductal gray matter and thalamus in sciatic nerve-ligated mice was similar to that in sham-operated mice. Antinociception induced by s.c., intrathecal, or intracerebroventricular injection of the morphine metabolite morphine-6-glucuronide (M-6-G) was significantly decreased by sciatic nerve ligation. Furthermore, the increase in the G-protein activation induced by M-6-G was eliminated in sciatic nerve ligation. In addition, either morphine-or oxycodone-induced rewarding effect was dramatically suppressed under a neuropathic pain-like state. The increased [ 35 S]GTPgS binding by morphine or oxycodone was significantly lower in the lower midbrain of mice with sciatic nerve ligation compared with that in control mice. These findings provide further evidence that oxycodone shows a profound antinociceptive effect under a neuropathic pain-like state with less of a rewarding effect. Furthermore, the reduction in G-protein activation induced by M-6-G may, at least in part, contribute to the suppression of the antinociceptive effect produced by morphine under a neuropathic pain-like state.

show abstract

Section: Inhibition Of Morphine-or Oxycodone-induced Place Preferencementioning

confidence: 81%

Comparative Pharmacological Profiles of Morphine and Oxycodone under a Neuropathic Pain-Like State in Mice: Evidence for Less Sensitivity to Morphine

Narita

Nakamura

Masahiko

et al. 2007

Neuropsychopharmacol

View full text Add to dashboard Cite

show abstract

“…121,122 Procedures include epidural or perineural injections of local anesthetics or corticosteroids, implantation of epidural and intrathecal drug delivery systems, neural ablative procedures (e.g., Gasserion ganglion glycerol injection or gamma knife surgery) and insertion of spinal cord stimulators, just to name a few. Consideration of highly invasive procedures such as insertion of intrathecal infusion pumps or spinal cord stimulators is generally reserved for patients with no surgically treatable pathology who have failed more conservative treatments and undergone psychological evaluation.…”

Section: Interventional Pain Managementmentioning

confidence: 99%

Neuropathic pain: a practical guide for the clinician

Gilron

Watson²,

Cahill³

et al. 2006

Canadian Medical Association Journal

378

275

View full text Add to dashboard Cite

“…Baclofen Baclofen (Lioresal, Novartis Pharmaceuticals Canada Inc), known primarily for its antispasticity action (217,218), has also been shown to have an antinociceptive action in a variety of experimental models, including nerve injury models (219). Baclofen selectively activates GABA-B receptors pre-and postsynaptically, leading to a decrease in excitatory transmission and an increase in inhibition, resulting in marked segmental inhibition.…”

Section: Physical Dependencementioning

confidence: 99%

The Pharmacotherapy of Chronic Pain: A Review

Lynch

Watson

2006

Pain Research and Management

101

View full text Add to dashboard Cite

The past two decades have contributed a large body of preclinical work that has assisted in our understanding of the underlying pathophysiological mechanisms that cause chronic pain. In this context, it has been recognized that effective treatment of pain is a priority and that treatment often involves the use of one or a combination of agents with analgesic action. The current review presents an evidence-based approach to the pharmacotherapy of chronic pain. Medline searches were done for all agents used as conventional treatment in chronic pain. Published papers up to June 2005 were included. The search strategy included randomized, controlled trials, and where available, systematic reviews and meta-analyses. Further references were found in reference sections of papers located using the above search strategy. Agents for which there were no controlled trials supporting efficacy in treatment of chronic pain were not included in the present review, except in cases where preclinical science was compelling, or where initial human work has been positive and where it was thought the reader would be interested in the scientific evidence to date.Key Words: Anticonvulsants; Antidepressants; Cannabinoids; Chronic pain; Opioids; Pharmacotherapy; Topical analgesics La pharmacothérapie de la douleur chronique : Une analyse Les deux dernières décennies ont contribué à un vaste ensemble de travaux précliniques qui nous ont permis de mieux comprendre les mécanismes physiopathologiques sous-jacents responsables de la douleur chronique. Dans ce contexte, il est admis que le traitement efficace de la douleur est une priorité et qu'il exige souvent le recours à un agent ou à une association d'agents ayant une action analgésique. La présente analyse présente une démarche probante de la pharmacothérapie de la douleur chronique. Des recherches dans Medline ont été effectuées sur tous les agents utilisés pour le traitement classique de la douleur chronique. Les articles publiés jusqu'en juin 2005 ont été inclus. La stratégie de recherche incluait les essais aléatoires et contrôlés et, si elles étaient disponibles, les analyses systématiques et les méta-analyses. D'autres références ont été obtenues dans la partie des références des articles trouvés à l'aide de la stratégie de recherche précédente. Les agents dont aucun essai contrôlé n'étayait l'efficacité pour le traitement de la douleur chronique étaient exclus de la présente analyse, sauf si les données scientifiques précliniques étaient convaincantes, si les travaux humains initiaux étaient positifs ou si on pensait que les données scientifiques colligées jusque-là étaient intéressantes pour le lecteur.

show abstract

Implantable devices for pain control: spinal cord stimulation and intrathecal therapies

Cited by 68 publications

References 92 publications

Comparative Pharmacological Profiles of Morphine and Oxycodone under a Neuropathic Pain-Like State in Mice: Evidence for Less Sensitivity to Morphine

Comparative Pharmacological Profiles of Morphine and Oxycodone under a Neuropathic Pain-Like State in Mice: Evidence for Less Sensitivity to Morphine

Neuropathic pain: a practical guide for the clinician

The Pharmacotherapy of Chronic Pain: A Review

Contact Info

Product

Resources

About